Description
This combination vial from Bolt Peptide assembles three well-characterized peptides, CJC-1295 without DAC, Ipamorelin, and Tesamorelin, into a single lyophilized format. The three sequences act on related but distinct nodes of the somatotropic axis, making the blend a convenient reference set for laboratories studying growth hormone-releasing pathways in a shared sample.
CJC-1295 (no DAC), sometimes referenced as modified GRF(1-29), is a short synthetic analog of growth hormone-releasing hormone. The “no DAC” designation indicates the molecule lacks the drug affinity complex moiety, giving it a shorter circulating profile than DAC-bearing versions and making it of interest for studies of pulsatile GHRH-receptor signaling.
Tesamorelin is a stabilized 44-amino-acid GHRH analog carrying an N-terminal modification that increases resistance to enzymatic breakdown relative to the native sequence. Ipamorelin is a selective pentapeptide of the growth hormone secretagogue class that engages the ghrelin receptor (GHS-R1a). Combining a secretagogue with two GHRH-type analogs lets researchers examine how distinct receptor inputs to the pituitary interact within one experimental system.
Common areas of non-clinical research interest include:
- GHRH-receptor and GHS-R1a receptor binding and signal transduction
- Comparative structure-activity studies across the three sequences
- Pituitary cell-model and somatotroph biology assays
- Peptide stability, solubility, and reconstitution chemistry
Each lot is offered as lyophilized powder and is supported by a Certificate of Analysis with identity and purity data determined by HPLC and mass spectrometry. Store vials cold and protected from light, and reconstitute with an appropriate sterile diluent following standard laboratory handling practice.
Research Use Only: This material is supplied strictly for laboratory research. Not for human or animal consumption. It is not a drug, food, supplement, or cosmetic and has not been approved by the FDA.


Reviews
There are no reviews yet.